-
Something wrong with this record ?
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
D. Zackova, H. Klamova, P. Belohlavkova, L. Stejskal, T. Necasova, L. Semerad, B. Weinbergerova, D. Srbova, J. Voglova, P. Cicatkova, Z. Sustkova, T. Hornak, J. Baranova, J. Prochazkova, J. Mayer
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Leukemia, Myeloid, Chronic-Phase * drug therapy genetics MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * drug therapy genetics MeSH
- Dasatinib adverse effects MeSH
- Imatinib Mesylate adverse effects MeSH
- Protein Kinase Inhibitors adverse effects MeSH
- Humans MeSH
- Retrospective Studies MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
Central European Institute of Technology Brno Czech Republic
Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
Institute of Hematology and Blood Transfusion Praha Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019574
- 003
- CZ-PrNML
- 005
- 20210830101152.0
- 007
- ta
- 008
- 210728s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2020.1827242 $2 doi
- 035 __
- $a (PubMed)33021423
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zackova, Daniela $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 245 10
- $a Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice / $c D. Zackova, H. Klamova, P. Belohlavkova, L. Stejskal, T. Necasova, L. Semerad, B. Weinbergerova, D. Srbova, J. Voglova, P. Cicatkova, Z. Sustkova, T. Hornak, J. Baranova, J. Prochazkova, J. Mayer
- 520 9_
- $a To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
- 650 _2
- $a dasatinib $x škodlivé účinky $7 D000069439
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imatinib mesylát $x škodlivé účinky $7 D000068877
- 650 12
- $a chronická myeloidní leukemie $x farmakoterapie $x genetika $7 D015464
- 650 12
- $a chronická fáze myeloidní leukemie $x farmakoterapie $x genetika $7 D015466
- 650 _2
- $a inhibitory proteinkinas $x škodlivé účinky $7 D047428
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Praha, Czech Republic
- 700 1_
- $a Belohlavkova, Petra $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Stejskal, Lukas $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Necasova, Tereza $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
- 700 1_
- $a Semerad, Lukas $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Weinbergerova, Barbora $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Srbova, Dana $u Institute of Hematology and Blood Transfusion, Praha, Czech Republic
- 700 1_
- $a Voglova, Jaroslava $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Cicatkova, Petra $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Sustkova, Zuzana $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Hornak, Tomas $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Baranova, Jana $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
- 700 1_
- $a Prochazkova, Jirina $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $u Central European Institute of Technology, Brno, Czech Republic
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 62, č. 1 (2021), s. 194-202
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33021423 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101152 $b ABA008
- 999 __
- $a ok $b bmc $g 1690415 $s 1140020
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 62 $c 1 $d 194-202 $e 20201006 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20210728
